Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 363

1.

Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin.

Eikelboom JW, Bosch JJ, Connolly SJ, Shestakovska O, Dagenais GR, Hart RG, Leong DP, O'Donnell M, Fox KAA, Bhatt DL, Cairns JA, Tasto C, Berkowitz SD, Cook Bruns N, Muehlhofer E, Diaz R, Maggioni AP, Yusuf S.

J Am Coll Cardiol. 2019 Sep 24;74(12):1519-1528. doi: 10.1016/j.jacc.2019.07.065.

2.

Aortic Arch Atherosclerosis in Patients With Embolic Stroke of Undetermined Source: An Exploratory Analysis of the NAVIGATE ESUS Trial.

Ntaios G, Pearce LA, Meseguer E, Endres M, Amarenco P, Ozturk S, Lang W, Bornstein NM, Molina CA, Pagola J, Mundl H, Berkowitz SD, Liu YY, Sen S, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators.

Stroke. 2019 Sep 17:STROKEAHA119025813. doi: 10.1161/STROKEAHA.119.025813. [Epub ahead of print]

PMID:
31526123
3.

Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial.

Perera KS, Ng KKH, Nayar S, Catanese L, Dyal L, Sharma M, Connolly SJ, Yusuf S, Bosch J, Eikelboom JW, Hart RG.

JAMA Neurol. 2019 Sep 16. doi: 10.1001/jamaneurol.2019.2984. [Epub ahead of print]

PMID:
31524941
4.

Bleeding and New Cancer Diagnosis in Patients with Atherosclerosis.

Eikelboom JW, Connolly SJ, Bosch J, Shestakovska O, Aboyans V, Alings M, Anand SS, Avezum A, Berkowitz SD, Bhatt DL, Cook Bruns N, Felix C, Fox KAA, Hart RG, Maggioni AP, Moayyedi P, O'Donnell M, Rydén L, Verhamme P, Widimsky P, Zhu J, Yusuf S; COMPASS investigators.

Circulation. 2019 Sep 12. doi: 10.1161/CIRCULATIONAHA.119.041949. [Epub ahead of print]

PMID:
31510769
5.

Efficacy and Safety of Rivaroxaban Versus Aspirin in Embolic Stroke of Undetermined Source and Carotid Atherosclerosis.

Ntaios G, Swaminathan B, Berkowitz SD, Gagliardi RJ, Lang W, Siegler JE, Lavados P, Mundl H, Bornstein N, Meseguer E, Amarenco P, Cucchiara B, Camps-Renom P, Makaritsis K, Korompoki E, Papavasileiou V, Marti-Fabregas J, Milionis H, Vemmos K, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators.

Stroke. 2019 Sep;50(9):2477-2485. doi: 10.1161/STROKEAHA.119.025168. Epub 2019 Aug 12.

PMID:
31401971
6.

Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.

Hart RG, Veltkamp RC, Sheridan P, Sharma M, Kasner SE, Bangdiwala SI, Ntaios G, Shoamanesh A, Ameriso SF, Toni D, Czlonkowska A, Lindgren A, Hankey GJ, Perera KS, Shuaib A, Coutts SB, Gagliardi RJ, Berkowitz SD, Mundl H, Peters G, Connolly SJ; NAVIGATE ESUS Investigators.

J Stroke Cerebrovasc Dis. 2019 Aug;28(8):2273-2279. doi: 10.1016/j.jstrokecerebrovasdis.2019.05.014. Epub 2019 May 31.

PMID:
31160218
7.

Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.

Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Bruns NC, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar AK, Parkhomenko AN, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne KP, Fox KAA, Yusuf S; COMPASS Investigators.

Gastroenterology. 2019 Sep;157(3):682-691.e2. doi: 10.1053/j.gastro.2019.05.056. Epub 2019 May 29.

PMID:
31152740
8.

Who says "no" to participating in stroke clinical trials and why: an observational study from the Vancouver Stroke Program.

O'Neill ZR, Deptuck HM, Quong L, Maclean G, Villaluna K, King-Azote P, Sharma M, Butcher K, Hart RG, Field TS.

Trials. 2019 May 31;20(1):313. doi: 10.1186/s13063-019-3434-0.

9.

Branch atheromatous disease diagnosed as embolic stroke of undetermined source: A sub-analysis of NAVIGATE ESUS.

Uchiyama S, Toyoda K, Kitagawa K, Okada Y, Ameriso S, Mundl H, Berkowitz S, Yamada T, Liu YY, Hart RG; NAVIGATE ESUS Investigators.

Int J Stroke. 2019 May 27:1747493019852177. doi: 10.1177/1747493019852177. [Epub ahead of print]

PMID:
31132967
10.

Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.

Moayyedi P, Eikelboom JW, Bosch J, Connolly SJ, Dyal L, Shestakovska O, Leong D, Anand SS, Störk S, Branch KRH, Bhatt DL, Verhamme PB, O'Donnell M, Maggioni AP, Lonn EM, Piegas LS, Ertl G, Keltai M, Cook Bruns N, Muehlhofer E, Dagenais GR, Kim JH, Hori M, Steg PG, Hart RG, Diaz R, Alings M, Widimsky P, Avezum A, Probstfield J, Zhu J, Liang Y, Lopez-Jaramillo P, Kakkar A, Parkhomenko AN, Ryden L, Pogosova N, Dans A, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik T, Vinereanu D, Tonkin AM, Lewis BS, Felix C, Yusoff K, Metsarinne K, Fox KAA, Yusuf S; COMPASS Investigators.

Gastroenterology. 2019 Aug;157(2):403-412.e5. doi: 10.1053/j.gastro.2019.04.041. Epub 2019 May 2.

PMID:
31054846
11.

Frequency and features of embolic stroke of undetermined source in young adults.

Perera KS, Swaminathan B, Veltkamp R, Arauz A, Ameriso S, Marti-Fabregas J, Arnold M, Hankey GJ, Lutsep H, Hart RG.

Eur Stroke J. 2018 Jun;3(2):110-116. doi: 10.1177/2396987318755585. Epub 2018 Jan 24.

12.

Recurrent Stroke With Rivaroxaban Compared With Aspirin According to Predictors of Atrial Fibrillation: Secondary Analysis of the NAVIGATE ESUS Randomized Clinical Trial.

Healey JS, Gladstone DJ, Swaminathan B, Eckstein J, Mundl H, Epstein AE, Haeusler KG, Mikulik R, Kasner SE, Toni D, Arauz A, Ntaios G, Hankey GJ, Perera K, Pagola J, Shuaib A, Lutsep H, Yang X, Uchiyama S, Endres M, Coutts SB, Karlinski M, Czlonkowska A, Molina CA, Santo G, Berkowitz SD, Hart RG, Connolly SJ.

JAMA Neurol. 2019 Jul 1;76(7):764-773. doi: 10.1001/jamaneurol.2019.0617.

PMID:
30958508
13.

Promoting Independent Mobility-related Physical ACTivity (IMPACT) in an inpatient stroke rehabilitation unit: a proof-of-concept evaluation of self-management intervention.

DePaul VG, Bosch J, Oczkowski WJ, Wishart L, O'Donnell M, Hart RG.

Disabil Rehabil. 2019 Mar 29:1-10. doi: 10.1080/09638288.2019.1587012. [Epub ahead of print]

PMID:
30924713
14.

Atrial Fibrillation and Cognitive Function: JACC Review Topic of the Week.

Diener HC, Hart RG, Koudstaal PJ, Lane DA, Lip GYH.

J Am Coll Cardiol. 2019 Feb 12;73(5):612-619. doi: 10.1016/j.jacc.2018.10.077. Review.

PMID:
30732716
15.

Stroke Outcomes in the COMPASS Trial.

Sharma M, Hart RG, Connolly SJ, Bosch J, Shestakovska O, Ng KKH, Catanese L, Keltai K, Aboyans V, Alings M, Ha JW, Varigos J, Tonkin A, O'Donnell M, Bhatt DL, Fox K, Maggioni A, Berkowitz SD, Bruns NC, Yusuf S, Eikelboom JW.

Circulation. 2019 Feb 26;139(9):1134-1145. doi: 10.1161/CIRCULATIONAHA.118.035864.

PMID:
30667279
16.

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial.

Kasner SE, Swaminathan B, Lavados P, Sharma M, Muir K, Veltkamp R, Ameriso SF, Endres M, Lutsep H, Messé SR, Spence JD, Nedeltechev K, Perera K, Santo G, Olavarria V, Lindgren A, Bangdiwala S, Shoamanesh A, Berkowitz SD, Mundl H, Connolly SJ, Hart RG; NAVIGATE ESUS Investigators.

Lancet Neurol. 2018 Dec;17(12):1053-1060. doi: 10.1016/S1474-4422(18)30319-3. Epub 2018 Sep 28. Erratum in: Lancet Neurol. 2018 Oct 23;:.

17.

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.

Hart RG, Connolly SJ, Mundl H.

N Engl J Med. 2018 Sep 6;379(10):987. doi: 10.1056/NEJMc1809065. No abstract available.

PMID:
30184459
18.

Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial.

Sharma M, Hart RG, Smith EE, Bosch J, Yuan F, Casanova A, Eikelboom JW, Connolly SJ, Wong G, Diaz R, Lopez-Jaramillo P, Ertl G, Störk S, Dagenais GR, Lonn EM, Ryden L, Tonkin AM, Varigos JD, Bhatt DL, Branch KR, Probstfield JL, Kim JH, Ha JW, O'Donnell M, Vinereanu D, Fox KA, Liang Y, Liu L, Zhu J, Pogosova N, Maggioni AP, Avezum A, Piegas LS, Keltai K, Keltai M, Cook Bruns N, Berkowitz S, Yusuf S.

Int J Stroke. 2019 Apr;14(3):270-281. doi: 10.1177/1747493018784478. Epub 2018 Jul 30.

PMID:
30058959
19.

Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.

Hart RG, Sharma M, Mundl H, Kasner SE, Bangdiwala SI, Berkowitz SD, Swaminathan B, Lavados P, Wang Y, Wang Y, Davalos A, Shamalov N, Mikulik R, Cunha L, Lindgren A, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi RJ, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni D, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, Endres M, Muir KW, Bornstein N, Ozturk S, O'Donnell MJ, De Vries Basson MM, Pare G, Pater C, Kirsch B, Sheridan P, Peters G, Weitz JI, Peacock WF, Shoamanesh A, Benavente OR, Joyner C, Themeles E, Connolly SJ; NAVIGATE ESUS Investigators.

N Engl J Med. 2018 Jun 7;378(23):2191-2201. doi: 10.1056/NEJMoa1802686. Epub 2018 May 16.

20.

Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial.

Kasner SE, Lavados P, Sharma M, Wang Y, Wang Y, Dávalos A, Shamalov N, Cunha L, Lindgren A, Mikulik R, Arauz A, Lang W, Czlonkowska A, Eckstein J, Gagliardi R, Amarenco P, Ameriso SF, Tatlisumak T, Veltkamp R, Hankey GJ, Toni DS, Bereczki D, Uchiyama S, Ntaios G, Yoon BW, Brouns R, DeVries Basson MM, Endres M, Muir K, Bornstein N, Ozturk S, O'Donnell M, Mundl H, Pater C, Weitz J, Peacock WF, Swaminathan B, Kirsch B, Berkowitz SD, Peters G, Pare G, Themeles E, Shoamanesh A, Connolly SJ, Hart RG; NAVIGATE ESUS Steering Committee and Investigators.

J Stroke Cerebrovasc Dis. 2018 Jun;27(6):1673-1682. doi: 10.1016/j.jstrokecerebrovasdis.2018.01.027. Epub 2018 Mar 7.

21.

Predictors of Mortality in Patients With Atrial Fibrillation (from the Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events [ACTIVE A]).

Perera KS, Pearce LA, Sharma M, Benavente O, Connolly SJ, Hart RG; ACTIVE A (Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators.

Am J Cardiol. 2018 Mar 1;121(5):584-589. doi: 10.1016/j.amjcard.2017.11.028. Epub 2017 Dec 11.

PMID:
29291887
22.

Embolic Stroke.

Ntaios G, Hart RG.

Circulation. 2017 Dec 19;136(25):2403-2405. doi: 10.1161/CIRCULATIONAHA.117.030509. No abstract available.

PMID:
29255121
23.

Nonmuscle myosin 2 proteins encoded by Myh9, Myh10, and Myh14 are uniquely distributed in the tubular segments of murine kidney.

Otterpohl KL, Hart RG, Evans C, Surendran K, Chandrasekar I.

Physiol Rep. 2017 Dec;5(23). doi: 10.14814/phy2.13513.

24.

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial.

Anand SS, Bosch J, Eikelboom JW, Connolly SJ, Diaz R, Widimsky P, Aboyans V, Alings M, Kakkar AK, Keltai K, Maggioni AP, Lewis BS, Störk S, Zhu J, Lopez-Jaramillo P, O'Donnell M, Commerford PJ, Vinereanu D, Pogosova N, Ryden L, Fox KAA, Bhatt DL, Misselwitz F, Varigos JD, Vanassche T, Avezum AA, Chen E, Branch K, Leong DP, Bangdiwala SI, Hart RG, Yusuf S; COMPASS Investigators.

Lancet. 2018 Jan 20;391(10117):219-229. doi: 10.1016/S0140-6736(17)32409-1. Epub 2017 Nov 10.

25.

Should Patients With Ischemic Stroke or Transient Ischemic Attack With Atrial Fibrillation and Microbleeds Be Anticoagulated?

Shoamanesh A, Charidimou A, Sharma M, Hart RG.

Stroke. 2017 Dec;48(12):3408-3412. doi: 10.1161/STROKEAHA.117.018467. Epub 2017 Nov 7. No abstract available.

PMID:
29114097
26.

Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, Widimsky P, Hori M, Avezum A, Piegas LS, Branch KRH, Probstfield J, Bhatt DL, Zhu J, Liang Y, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Kakkar AK, Fox KAA, Parkhomenko AN, Ertl G, Störk S, Keltai M, Ryden L, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Tonkin AM, Lewis BS, Felix C, Yusoff K, Steg PG, Metsarinne KP, Cook Bruns N, Misselwitz F, Chen E, Leong D, Yusuf S; COMPASS Investigators.

N Engl J Med. 2017 Oct 5;377(14):1319-1330. doi: 10.1056/NEJMoa1709118. Epub 2017 Aug 27.

27.

Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial.

Bosch J, Eikelboom JW, Connolly SJ, Bruns NC, Lanius V, Yuan F, Misselwitz F, Chen E, Diaz R, Alings M, Lonn EM, Widimsky P, Hori M, Avezum A, Piegas LS, Bhatt DL, Branch KRH, Probstfield JL, Liang Y, Liu L, Zhu J, Maggioni AP, Lopez-Jaramillo P, O'Donnell M, Fox KAA, Kakkar A, Parkhomenko AN, Ertl G, Störk S, Keltai K, Keltai M, Ryden L, Dagenais GR, Pogosova N, Dans AL, Lanas F, Commerford PJ, Torp-Pedersen C, Guzik TJ, Verhamme PB, Vinereanu D, Kim JH, Ha JW, Tonkin AM, Varigos JD, Lewis BS, Felix C, Yusoff K, Steg PG, Aboyans V, Metsarinne KP, Anand SS, Hart RG, Lamy A, Moayyedi P, Leong DP, Sharma M, Yusuf S.

Can J Cardiol. 2017 Aug;33(8):1027-1035. doi: 10.1016/j.cjca.2017.06.001. Epub 2017 Jun 8. Review.

28.

Microbleeds in the Secondary Prevention of Small Subcortical Strokes Trial: Stroke, mortality, and treatment interactions.

Shoamanesh A, Pearce LA, Bazan C, Catanese L, McClure LA, Sharma M, Marti-Fabregas J, Anderson DC, Kase CS, Hart RG, Benavente OR; SPS3 Trial Investigators.

Ann Neurol. 2017 Aug;82(2):196-207. doi: 10.1002/ana.24988. Epub 2017 Jul 19.

29.

Embolic Stroke of Undetermined Source: A Systematic Review and Clinical Update.

Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ.

Stroke. 2017 Apr;48(4):867-872. doi: 10.1161/STROKEAHA.116.016414. Epub 2017 Mar 6. Review.

PMID:
28265016
30.

Is There a Role for Betrixaban to Prevent Stroke in Medically Ill Patients?

Quinlan DJ, Eikelboom JW, Hart RG.

Circulation. 2017 Feb 14;135(7):656-658. doi: 10.1161/CIRCULATIONAHA.116.026170. No abstract available.

PMID:
28193799
31.

The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation: A Review.

Hess PL, Healey JS, Granger CB, Connolly SJ, Ziegler PD, Alexander JH, Kowey PR, Ruff CT, Flaker G, Halperin JL, Hart RG, Lopes RD.

JAMA Cardiol. 2017 Mar 1;2(3):324-331. doi: 10.1001/jamacardio.2016.5167. Review.

PMID:
28097334
32.

Which Patients With Atrial Fibrillation and Chronic Kidney Disease Should Receive Anticoagulation-And With Which Anticoagulant?

Hart RG, Ingram AJ, Eikelboom JW.

Can J Cardiol. 2017 Feb;33(2):211-213. doi: 10.1016/j.cjca.2016.10.007. Epub 2016 Oct 17. No abstract available.

PMID:
27998618
33.

Rivaroxaban for secondary stroke prevention in patients with embolic strokes of undetermined source: Design of the NAVIGATE ESUS randomized trial.

Hart RG, Sharma M, Mundl H, Shoamanesh A, Kasner SE, Berkowitz SD, Pare G, Kirsch B, Pogue J, Pater C, Peters G, Davalos A, Lang W, Wang Y, Wang Y, Cunha L, Eckstein J, Tatlisumak T, Shamalov N, Mikulik R, Lavados P, Hankey GJ, Czlonkowska A, Toni D, Ameriso SF, Gagliardi RJ, Amarenco P, Bereczki D, Uchiyama S, Lindgren A, Endres M, Brouns R, Yoon BW, Ntaios G, Veltkamp R, Muir KW, Ozturk S, Arauz A, Bornstein N, Bryer A, O'Donnell MJ, Weitz J, Peacock F, Themeles E, Connolly SJ.

Eur Stroke J. 2016 Sep;1(3):146-154. doi: 10.1177/2396987316663049. Epub 2016 Aug 3.

34.

Antithrombotic Treatments for Stroke Prevention in Elderly Patients With Nonvalvular Atrial Fibrillation: Drugs and Doses.

Kilickap M, Bosch J, Eikelboom JW, Hart RG.

Can J Cardiol. 2016 Sep;32(9):1108-16. doi: 10.1016/j.cjca.2016.06.003. Epub 2016 Jun 14. Review.

PMID:
27568871
35.

Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke: Embolic Stroke of Undetermined Source Global Registry.

Perera KS, Vanassche T, Bosch J, Swaminathan B, Mundl H, Giruparajah M, Barboza MA, O'Donnell MJ, Gomez-Schneider M, Hankey GJ, Yoon BW, Roxas A Jr, Lavallee P, Sargento-Freitas J, Shamalov N, Brouns R, Gagliardi RJ, Kasner SE, Pieroni A, Vermehren P, Kitagawa K, Wang Y, Muir K, Coutinho JM, Connolly SJ, Hart RG; ESUS Global Registry Investigators.

Stroke. 2016 Sep;47(9):2197-202. doi: 10.1161/STROKEAHA.116.013378. Epub 2016 Aug 9.

36.

Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study.

O'Donnell MJ, Eikelboom JW, Yusuf S, Diener HC, Hart RG, Smith EE, Gladstone DJ, Sharma M, Dias R, Flaker G, Avezum A, Zhu J, Lewis G, Connolly S.

Am Heart J. 2016 Aug;178:145-50. doi: 10.1016/j.ahj.2016.03.019. Epub 2016 Apr 17.

PMID:
27502862
37.

Stroke: How good is aspirin for patients with acute brain ischaemia?

Hart RG, Eikelboom JW.

Nat Rev Neurol. 2016 Aug;12(8):434-5. doi: 10.1038/nrneurol.2016.97. Epub 2016 Jul 8. Review. No abstract available.

PMID:
27389094
38.

Rapid reversal of haematoma expansion associated with vitamin K antagonists.

Eikelboom JW, Bosch J, Hart RG.

Lancet Neurol. 2016 May;15(6):535-7. doi: 10.1016/S1474-4422(16)30008-4. Epub 2016 Apr 11. No abstract available.

PMID:
27302113
39.

Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry.

Perera KS, Vanassche T, Bosch J, Giruparajah M, Swaminathan B, Mattina KR, Berkowitz SD, Arauz A, O'Donnell MJ, Ameriso SF, Hankey GJ, Yoon BW, Lavallee P, Cunha L, Shamalov N, Brouns R, Gagliardi RJ, Kasner SE, Pieroni A, Vermehren P, Kitagawa K, Wang Y, Muir K, Coutinho J, Vastagh I, Connolly SJ, Hart RG; ESUS Global Registry Investigators.

Int J Stroke. 2016 Jul;11(5):526-33. doi: 10.1177/1747493016641967. Epub 2016 Apr 11.

PMID:
27256472
40.

Age disparity in diagnostic evaluation of stroke patients: Embolic Stroke of Undetermined Source Global Registry Project.

Siegler JE, Swaminathan B, Giruparajah M, Bosch J, Perera KS, Hart RG, Kasner SE; ESUS Global Registry Investigators.

Eur Stroke J. 2016 Jun;1(2):130-138. doi: 10.1177/2396987316652265. Epub 2016 Jun 1.

41.

A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes study.

McClure LA, Szychowski JM, Benavente O, Hart RG, Coffey CS.

Clin Trials. 2016 Oct;13(5):537-44. doi: 10.1177/1740774516643689. Epub 2016 Apr 19.

42.

Use of Warfarin at Discharge Among Acute Ischemic Stroke Patients With Nonvalvular Atrial Fibrillation in China.

Yang X, Li Z, Zhao X, Wang C, Liu L, Wang C, Pan Y, Li H, Wang D, Hart RG, Wang Y, Wang Y; China National Stroke Registry II Investigators.

Stroke. 2016 Feb;47(2):464-70. doi: 10.1161/STROKEAHA.115.011833. Epub 2015 Dec 22.

PMID:
26696643
43.

Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.

Ng KH, Shestakovska O, Connolly SJ, Eikelboom JW, Avezum A, Diaz R, Lanas F, Yusuf S, Hart RG.

Age Ageing. 2016 Jan;45(1):77-83. doi: 10.1093/ageing/afv156. Epub 2015 Nov 19.

PMID:
26590293
44.

Achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial.

Odden MC, McClure LA, Sawaya BP, White CL, Peralta CA, Field TS, Hart RG, Benavente OR, Pergola PE.

Hypertension. 2016 Jan;67(1):63-9. doi: 10.1161/HYPERTENSIONAHA.115.06480. Epub 2015 Nov 9.

45.

Rapid Assessment and Treatment of Transient Ischemic Attacks and Minor Stroke in Canadian Emergency Departments: Time for a Paradigm Shift.

Kamal N, Hill MD, Blacquiere DP, Boulanger JM, Boyle K, Buck B, Butcher K, Camden MC, Casaubon LK, Côté R, Demchuk AM, Dowlatshahi D, Dubuc V, Field TS, Ghrooda E, Gioia L, Gladstone DJ, Goyal M, Gubitz GJ, Harris D, Hart RG, Hunter G, Jeerakathil T, Jin A, Khan K, Lang E, Lanthier S, Lindsay MP, Mackey A, Mandzia J, Mehdiratta M, Minuk J, Oczkowski W, Odier C, Penn A, Perry J, Pettersen JA, Phillips SJ, Poppe AY, Saposnik G, Selchen D, Shamy M, Sharma M, Shoamanesh A, Shuaib A, Silver F, Stotts G, Swartz R, Tamayo A, Teitelbaum J, Verreault S, Wein T, Yip S, Coutts SB.

Stroke. 2015 Oct;46(10):2987-90. doi: 10.1161/STROKEAHA.115.010454. Epub 2015 Aug 27. No abstract available.

PMID:
26316346
46.

What's new in stroke? Phase III randomized clinical trials of 2012-2014.

Hart RG, Ng KH, Perera KS, Shoamanesh A.

Int J Stroke. 2015 Aug;10(6):790-5. doi: 10.1111/ijs.12570. Epub 2015 Jul 14. Review.

PMID:
26178842
47.

Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction.

Jolly SS, Cairns JA, Yusuf S, Meeks B, Gao P, Hart RG, Kedev S, Stankovic G, Moreno R, Horak D, Kassam S, Rokoss MJ, Leung RC, El-Omar M, Romppanen HO, Alazzoni A, Alak A, Fung A, Alexopoulos D, Schwalm JD, Valettas N, Džavík V; TOTAL Investigators.

Eur Heart J. 2015 Sep 14;36(35):2364-72. doi: 10.1093/eurheartj/ehv296. Epub 2015 Jun 29.

48.

Global survey of the diagnostic evaluation and management of cryptogenic ischemic stroke.

Giruparajah M, Bosch J, Vanassche T, Mattina K, Connolly SJ, Pater C, Hart RG.

Int J Stroke. 2015 Oct;10(7):1031-6. doi: 10.1111/ijs.12509. Epub 2015 May 18.

PMID:
25982709
49.

Cognitive performance following lacunar stroke in Spanish-speaking patients: results from the SPS3 trial.

Jacova C, Pearce LA, Roldan AM, Arauz A, Tapia J, Costello R, McClure LA, Hart RG, Benavente OR.

Int J Stroke. 2015 Jun;10(4):519-28. doi: 10.1111/ijs.12511.

50.

Supplemental Content

Support Center